CN103524502B - 制备他达拉非的方法 - Google Patents
制备他达拉非的方法 Download PDFInfo
- Publication number
- CN103524502B CN103524502B CN201310472456.3A CN201310472456A CN103524502B CN 103524502 B CN103524502 B CN 103524502B CN 201310472456 A CN201310472456 A CN 201310472456A CN 103524502 B CN103524502 B CN 103524502B
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- compound shown
- contacted
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 29
- 150000001875 compounds Chemical class 0.000 claims abstract description 83
- 238000004519 manufacturing process Methods 0.000 claims abstract description 16
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 20
- 239000002904 solvent Substances 0.000 claims description 20
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 12
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical group CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 10
- 235000015320 potassium carbonate Nutrition 0.000 claims description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical group CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 abstract description 35
- 238000002360 preparation method Methods 0.000 abstract description 8
- 239000002994 raw material Substances 0.000 abstract description 7
- 230000008901 benefit Effects 0.000 abstract description 4
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 238000003756 stirring Methods 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 229940126214 compound 3 Drugs 0.000 description 7
- 229940125782 compound 2 Drugs 0.000 description 6
- 229940125898 compound 5 Drugs 0.000 description 5
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- WOXKDUGGOYFFRN-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 WOXKDUGGOYFFRN-IIBYNOLFSA-N 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical group C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- 101100296726 Caenorhabditis elegans pde-5 gene Proteins 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960000835 tadalafil Drugs 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310472456.3A CN103524502B (zh) | 2013-03-14 | 2013-10-11 | 制备他达拉非的方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310081086.0 | 2013-03-14 | ||
CN201310081086 | 2013-03-14 | ||
CN201310472456.3A CN103524502B (zh) | 2013-03-14 | 2013-10-11 | 制备他达拉非的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103524502A CN103524502A (zh) | 2014-01-22 |
CN103524502B true CN103524502B (zh) | 2015-11-25 |
Family
ID=49926901
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310472456.3A Expired - Fee Related CN103524502B (zh) | 2013-03-14 | 2013-10-11 | 制备他达拉非的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103524502B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105541835B (zh) * | 2015-12-31 | 2017-12-05 | 湖南千金湘江药业股份有限公司 | 顺式四氢咔啉中间体及其合成方法和在制备他达拉非方面的应用 |
CN109970739B (zh) * | 2017-12-28 | 2023-03-28 | 中美华世通生物医药科技(武汉)股份有限公司 | 合成他达拉非的方法 |
-
2013
- 2013-10-11 CN CN201310472456.3A patent/CN103524502B/zh not_active Expired - Fee Related
Non-Patent Citations (2)
Title |
---|
First highly stereocontrolled synthesis of tetrahydro trans-β-carboline derivatives by exploiting the influence of acyclic amide;Ravindra Vedantham, et al.;《ARKIVOC》;20120905;第2013卷(第2期);第22-32页 * |
Synthesis and characterization of related substances and metabolite of tadalafil, a PDE-5 inhibitor;Goverdhan Gilla, et al.;《Org. commun.》;20130305;第6卷(第1期);第12-22页 * |
Also Published As
Publication number | Publication date |
---|---|
CN103524502A (zh) | 2014-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104045637B (zh) | 一种阿哌沙班的制备方法 | |
CN105732622B (zh) | 一种阿哌沙班的制备方法 | |
CN104876995A (zh) | 鹅去氧胆酸衍生物的制备方法 | |
CN103772384A (zh) | 一种制备他达拉非的方法 | |
CN111440188B (zh) | 一种瑞卢戈利(Relugolix)关键中间体的制备方法 | |
CN102584820A (zh) | 一种5-溴-7-氮杂吲哚的制备方法 | |
CN103524502B (zh) | 制备他达拉非的方法 | |
CN102367260A (zh) | 2-氨基嘧啶-5-硼酸的合成方法 | |
CN101735023A (zh) | 一种3-溴-5-氯苯酚的制备方法 | |
CN104193765A (zh) | 一种头孢克肟的合成方法 | |
CN103459392A (zh) | 一种制备培美曲塞盐的方法 | |
CN102167716A (zh) | 氯法拉滨的合成方法及其中间体和中间体的制备方法 | |
CN105440012A (zh) | 一种来那度胺及其中间体的制备方法 | |
CN105732754A (zh) | 烷基酸睾酮化合物的合成方法 | |
CN103664952A (zh) | 一种佐匹克隆的制备方法 | |
CN103787968B (zh) | 化合物的制备方法 | |
CN101973909B (zh) | 一种米屈肼的制备方法 | |
CN104672180B (zh) | 一种[(1s)‑3‑甲基‑1‑[[(2r)‑2‑甲基环氧乙基]羰基]丁基]氨基甲酸叔丁酯的手性制备方法 | |
CN109020874B (zh) | 一种阿哌沙班中间体及其制备方法 | |
CN104693157A (zh) | 一种2-c-甲基-d-核糖酸-1,4-内酯的制备方法 | |
CN102161660B (zh) | 2-(6-氯-2-甲基嘧啶-4-胺基)-n-(2-氯-6-甲基苯基)-5-噻唑甲酰胺的制备方法 | |
CN103922959A (zh) | 一种有机合成中间体乙酰氨基丙二酸二乙酯的制备方法 | |
CN104961675A (zh) | 一种艾沙康唑中间体的制备方法 | |
CN110724084A (zh) | (s)-3-羟基-1-苄基吡咯烷的合成方法 | |
CN109970739B (zh) | 合成他达拉非的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20151028 Address after: The comprehensive office building of 430075 Hubei city of Wuhan province East Lake high tech Development Zone Road No. 666 humanwell Pharmaceutical Group Applicant after: HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE Inc. Address before: The comprehensive office building of 430075 Hubei city of Wuhan province East Lake high tech Development Zone Road No. 666, room 718, humanwell Pharmaceutical Group Applicant before: HUMANWELL HEALTHCARE (GROUP) Co.,Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151125 |